Loading stock data…
PVLA
$126.84-1.48 (-1.15%)
Market ClosedLast close May 1
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Palvella Therapeutics, Inc. in the Healthcare sector is trading at $126.84. The stock is currently near its 52-week high of $151.18, remaining 47.7% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why PVLA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$126.84
Potential Upside
5%
Whystock Fair Value$133.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$230.07+81.4%
Range$205.00 – $270.00
Fundamentals
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.07%
Volume
Today's trading volume
156,804
Recent News
New Palvella Director Brings Rare Disease Insight To Low Valued Stock
Palvella Therapeutics (NasdaqCM:PVLA) has appointed Dr. John D. Doux to its Board of Directors. Dr. Doux is a board-certified dermatologist and experienced healthcare investor with prior board experience. His appointment aligns with Palvella’s focus on therapies for rare dermatological diseases. For investors tracking Palvella Therapeutics, the appointment of Dr. John D. Doux comes at a time when the shares trade around $123.59 and the stock has a very large 1 year return. Year to date, the...
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said Axel-Sven Malkomes joined the company as Chief Financial Officer, while Susan Coles and Pamela Herbster started their roles as Chief Legal Officer and Chief People Officer, respectively. The additions come as Inventiva prepares for potential commercialization from the Phase 3 trial of its MASH therapeutic, expected in […]
Palvella’s Phase III Success And Fast Track Status Test Current Valuation
Palvella Therapeutics (NasdaqCM:PVLA) reported positive Phase III results for its lead therapy targeting a rare disease with significant unmet medical need. The company secured substantial new financing and expanded its rare disease pipeline with additional candidates. Palvella received FDA Fast-Track designation for its lead program, supporting a potentially accelerated review process. The company appointed a new Senior Vice President of Market Access and Patient Services to prepare for...
Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Palvella Therapeutics Inc (PVLA) reports robust financial positioning and promising clinical developments, despite regulatory challenges.
Palvella Therapeutics Q4 Earnings Call Highlights
Palvella Therapeutics (NASDAQ:PVLA) executives used the company’s full-year 2025 financial results call to highlight clinical progress across its rare disease pipeline, outline upcoming regulatory and commercial milestones for its lead program, and discuss a financing that management said positions